- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05843786
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)
Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation.
Post-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR < 8000 AB/C
All reported data about recombinant human IFNγ 1b for the control of secondary infections in patients with septic shock used the dose of 100 micrograms per day by subcutaneous route for 3 to 5 days . At this dose, no retrospective study has reported any serious adverse effects and recombinant human IFNγ 1b allows an increase in monocyte membrane expression of mHLA-DR.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Anne-Claire LUKASZEWICZ, Pr
- Phone Number: +33 472 11 13 27
- Email: anne-claire.lukaszewicz@chu-lyon.fr
Study Contact Backup
- Name: Camille BOUCHENY
- Phone Number: +33 4 26 73 27 39
- Email: Camille.boucheny@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69003
- Recruiting
- Service civilo-militaire d'Anesthésie-Réanimation et Médecine Périopératoire
-
Contact:
- Anne-Claire LUKASZEWICZ, Pr
-
Principal Investigator:
- Anne-Claire LUKASZEWICZ, Pr
-
Lyon, France, 69004
- Not yet recruiting
- Service de reanimation chirurgicale Hopital Croix-Rousse
-
Contact:
- Marie-Charlotte DELIGNETTE, MD
- Phone Number: +33 4 72 11 89 47
- Email: marie-charlotte.delignette@chu-lyon.fr
-
Principal Investigator:
- Marie-Charlotte DELIGNETTE, MD
-
Lyon, France, 69004
- Recruiting
- Service de reanimation médicale hôpital de la Croix-Rousse
-
Contact:
- Jean-Christophe RICHARD, Pr
- Phone Number: +33 4 26 10 92 72
- Email: j-christophe.richard@chu-lyon.fr
-
Principal Investigator:
- Jean-Christophe RICHARD, Pr
-
Nancy, France, 54511
- Not yet recruiting
- Service d'anesthésie-réanimation, unité de réanimation chirurgicale Picard
-
Contact:
- Marie-Reine Marie-Reine LOSSER, Pr
- Phone Number: +33 3 83 15 41 66
- Email: mr.losser@chru-nancy.fr
-
Principal Investigator:
- Marie-Reine LOSSER, Pr
-
Paris, France, 75014
- Not yet recruiting
- Médecine intensive- Réanimation
-
Contact:
- Frederic PENE, Pr
- Phone Number: +33 1 58 41 25 36
- Email: frederic.pene@aphp.fr
-
Principal Investigator:
- Frederic PENE, Pr
-
Pierre-Bénite, France, 69395
- Recruiting
- Service d'Anesthésie-réanimation-médecine intensive Hôpital Lyon Sud
-
Principal Investigator:
- Florent WALLET, MD
-
Contact:
- Florent WALLET, MD
- Phone Number: +33 4 78 86 19 21
- Email: florent.wallet@chu-lyon.fr
-
Saint-Étienne, France, 42055
- Not yet recruiting
- Département Anesthésie-Réanimation
-
Contact:
- Ludivine PETIT, MD
- Phone Number: +33 6 77 81 86 87
- Email: Ludivine.Petit@chu-st-etienne.fr
-
Principal Investigator:
- Ludivine PETIT, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- adult patients hospitalized in intensive care unit
- under mechanical ventilation for more than 5 days
- having a first episode of VAP (with a Clinical Pulmonary Infectious Score (CPIS score) >6)
- treated with antibiotics for less than 24 hours
- with monocyte HLA-DR < 8000 AB/C
Exclusion Criteria:
- Noradrenaline > 0.25 mcg/kg/min
Immunosuppression, defined by:
- solid tumor with chemotherapy in the last 3 months
- progressive metastatic disease
- hematological disease
- solid organ transplantation
- HIV infection (AIDS stage or not)
- corticosteroid therapy at any dose for more than 3 months
- ≥ 1 mg/kg of Prednisone equivalent for more than 7 days
- immunosuppressive therapy
- Head and/or cervical spine trauma
- Cardiocirculatory arrest
- Burn patient
- Cirrhosis with Child B or C score
- Infection with Aspergillus spp.
- Refusal to participate
- Patient participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (excluding interventional research of 2° not interfering with the endpoints of the study according to the judgment of the principal investigator)
- Lack of social coverage
- Patient under curatorship or guardianship
- Pregnant or breastfeeding women
- Patient admitted to intensive care for SARS-Cov2 pneumonia
- Known allergy to latex
- Hypersensitivity to the active substance (interferon gamma-1b) or known hypersensitivity to related products, such as another interferon, or to any of the following excipients: Mannitol, Disodium succinate hexahydrate, Succinic acid, polysorbate 20
- Existence of chronic heart disease with FeVG<45%
- Major hepatic impairment (total bilirubin>60 mg/L or 102 mcmol/L, equivalent to 3 SOFA points)
- thrombocytopenia <50000/mm3 (equivalent to 3 SOFA points) AST and/or ALT > 5N Lipase > 3N Severe chronic renal failure (creatinine clearance MDRD< 10 ml/min/1.73m2)
- Thrombocytopenia <50,000/mm3 (equivalent to 3 SOFA points)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interferon gamma treatment
Interferon gamma treatment (100 micrograms /day during 5 days)
|
Daily subcutaneous administration of Interferon gamma during 5 days
|
Placebo Comparator: Placebo
The comparator drug (placebo) is an injectable solution of sodium chloride 0.9%
|
Placebo during 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
duration of mechanical ventilation assessed from the first day of VAP diagnosis
Time Frame: Day 28
|
mechanical ventilation-free days (VFD) from extubation through D28.
A beneficial effect of using recombinant human interferon gamma-1b would be a statistically significant increase in VFD in patients receiving study drug in this setting compared to the group receiving placebo.
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality in intensive care
Time Frame: Day 28
|
Day 28
|
|
Previous positive microbiological sample at inclusion becomes negative
Time Frame: Day 5
|
Previous positive microbiological sample at inclusion becomes negative, i.e. pulmonary, urinary, blood cultures
|
Day 5
|
Length of stay in intensive care unit
Time Frame: Day 28
|
Day 28
|
|
length of stay at hospital
Time Frame: Day 28
|
Day 28
|
|
occurrence of another episode of VAP before extubation
Time Frame: Day 28
|
Day 28
|
|
occurrence of another episode of infection acquired in intensive care unit
Time Frame: Day 28
|
Day 28
|
|
increase of monocytic HLA-DR expression above 8000 AB/C the day after the last dose of treatment (J5)
Time Frame: Day 28
|
Day 28
|
|
increase or decrease of blood leucocyte count at the day after the last dose of treatment (J5) in comparison to baseline
Time Frame: Day 28
|
Day 28
|
|
Evaluation of the economic efficiency of the administration of IFN-γ (assessed by the ACER (average cost-effectiveness ratio) method)
Time Frame: Day 28
|
Evaluation of the cost-effectiveness of IFN-γ administration (assessed by the ACER (average cost-effectiveness ratio) method)
|
Day 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne-Claire LUKASZEWICZ, Pr, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Pneumonia
- Pneumonia, Ventilator-Associated
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Interferons
- Interferon-gamma
Other Study ID Numbers
- 69HCL22_0851
- 2022-502229-16-00 (Other Identifier: EUCT number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Ventilator-Associated
-
Hospital Alemão Oswaldo CruzMinistry of Health, BrazilRecruitingHealthcare-Associated Pneumonia | Ventilator-Associated Pneumonia | Healthcare Associated InfectionBrazil
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Cubist Pharmaceuticals LLCCompletedLung Diseases | Healthcare-Associated Pneumonia | Ventilator-Associated Pneumonia
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
University Hospital OlomoucCompletedVentilator-Associated Pneumonia
-
Aydin Adnan Menderes UniversityNot yet recruitingVentilator-Associated PneumoniaTurkey
-
Istanbul Medeniyet UniversityRecruiting
-
University Hospital, ToulouseRecruitingVentilator-associated PneumoniaFrance
-
Erasmus Medical CenterChiesi Farmaceutici S.p.A.CompletedVentilator Associated Pneumonia (VAP)Spain, Netherlands
-
Andrzej Frycz Modrzewski Krakow UniversityCompletedVAP - Ventilator Associated PneumoniaPoland
Clinical Trials on Interferon gamma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Horizon Pharma USA, Inc.TerminatedMyxoid Liposarcoma | Synovial Sarcoma | Round Cell LiposarcomaUnited States
-
SPP Pharmaclon Ltd.RecruitingPulmonary TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.CompletedCommunity-acquired PneumoniaRussian Federation
-
SPP Pharmaclon Ltd.RecruitingRespiratory TuberculosisRussian Federation
-
SPP Pharmaclon Ltd.North-Western State Medical University named after I.I.MechnikovCompletedRNA Virus Infections | Lentivirus Infections | Tuberculosis, Pulmonary | Human Immunodeficiency Virus | HIV Coinfection | Aids/Hiv ProblemRussian Federation
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)CompletedTuberculosis | AIDS-related ComplexUnited States, South Africa
-
SPP Pharmaclon Ltd.CompletedCOVID-19 Respiratory Infection | Viral PneumoniaRussian Federation
-
Nantes University HospitalActive, not recruiting
-
SPP Pharmaclon Ltd.Completed
-
SPP Pharmaclon Ltd.CompletedHuman Papillomavirus Infection | Anogenital WartsRussian Federation